Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,333 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $18.43, for a total transaction of $337,877.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of DNLI opened at $19.57 on Friday. Denali Therapeutics Inc has a twelve month low of $12.32 and a twelve month high of $25.79.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13). The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $3.00 million. Sell-side analysts forecast that Denali Therapeutics Inc will post -1.37 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on DNLI. Cantor Fitzgerald set a $25.00 price objective on shares of Denali Therapeutics and gave the company a “buy” rating in a research note on Friday. Janney Montgomery Scott began coverage on shares of Denali Therapeutics in a research note on Monday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Finally, Zacks Investment Research cut shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $24.00.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ballentine Partners LLC purchased a new stake in Denali Therapeutics during the 3rd quarter valued at $544,000. BlackRock Inc. boosted its position in Denali Therapeutics by 6.4% during the 2nd quarter. BlackRock Inc. now owns 1,121,358 shares of the company’s stock valued at $17,101,000 after buying an additional 67,420 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new stake in Denali Therapeutics during the 2nd quarter valued at $278,000. Bank of New York Mellon Corp boosted its position in Denali Therapeutics by 17.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 61,196 shares of the company’s stock valued at $933,000 after buying an additional 8,882 shares during the period. Finally, Wasatch Advisors Inc. boosted its position in Denali Therapeutics by 90.4% during the 3rd quarter. Wasatch Advisors Inc. now owns 59,269 shares of the company’s stock valued at $1,289,000 after buying an additional 28,138 shares during the period. 70.52% of the stock is owned by institutional investors and hedge funds.
WARNING: “Insider Selling: Denali Therapeutics Inc (DNLI) Insider Sells 18,333 Shares of Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/12/08/insider-selling-denali-therapeutics-inc-dnli-insider-sells-18333-shares-of-stock.html.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: Catch-Up Contributions
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.